



US008592397B2

(12) **United States Patent**  
**Dahl et al.**

(10) **Patent No.:** **US 8,592,397 B2**  
(45) **Date of Patent:** **Nov. 26, 2013**

(54) **COMPOSITIONS AND METHODS FOR COMBINATION ANTIVIRAL THERAPY**

(75) Inventors: **Terrence C. Dahl**, Sunnyvale, CA (US);  
**Mark M. Menning**, San Francisco, CA (US); **Reza Oliyai**, San Carlos, CA (US)

(73) Assignee: **Gilead Sciences, Inc.**, Foster City, CA (US)

(\*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

(21) Appl. No.: **12/195,161**

(22) Filed: **Aug. 20, 2008**

(65) **Prior Publication Data**

US 2009/0143314 A1 Jun. 4, 2009

#### Related U.S. Application Data

(63) Continuation of application No. 10/540,794, filed as application No. PCT/US2004/000832 on Jan. 13, 2004, now abandoned.

(60) Provisional application No. 60/440,246, filed on Jan. 14, 2003, provisional application No. 60/440,308, filed on Jan. 14, 2003.

(51) **Int. Cl.**  
**A61K 31/675** (2006.01)

(52) **U.S. Cl.**  
USPC ..... **514/81**

(58) **Field of Classification Search**  
USPC ..... 514/45; 424/400, 408  
See application file for complete search history.

(56) **References Cited**

#### U.S. PATENT DOCUMENTS

3,524,846 A 8/1970 Moffatt et al.  
3,622,677 A 11/1971 Short et al.  
3,682,930 A 8/1972 Bourquin et al.  
3,994,974 A 11/1976 Murakami et al.  
4,003,878 A 1/1977 Skaar et al.  
4,258,062 A 3/1981 Jonas et al.  
4,355,032 A 10/1982 Verheyden et al.  
4,384,005 A 5/1983 McSweeney  
4,430,343 A 2/1984 Iemura et al.  
4,476,248 A 10/1984 Gordon et al.  
4,724,233 A 2/1988 De Clercq et al.  
4,808,716 A 2/1989 Holy et al.  
4,816,570 A 3/1989 Farquhar  
4,879,288 A 11/1989 Warawa et al.  
4,957,924 A 9/1990 Beauchamp  
4,968,788 A 11/1990 Farquhar  
5,047,407 A 9/1991 Belleau et al.  
5,075,445 A 12/1991 Jarvest et al.  
5,142,051 A 8/1992 Holy et al.  
5,151,426 A 9/1992 Belleau et al.  
5,155,268 A 10/1992 Hester  
5,177,064 A 1/1993 Bodor  
5,179,104 A 1/1993 Chu et al.  
5,204,466 A 4/1993 Liotta et al.  
5,208,221 A 5/1993 Kim et al.  
5,210,085 A 5/1993 Liotta et al.

5,386,030 A 1/1995 Kim et al.  
5,466,806 A 11/1995 Belleau et al.  
5,476,938 A 12/1995 Vemishetti et al.  
5,486,520 A 1/1996 Belleau et al.  
5,506,347 A 4/1996 Erion et al.  
5,512,596 A 4/1996 Kim et al.  
5,514,798 A 5/1996 Bischofberger et al.  
5,538,975 A 7/1996 Dionne  
5,587,480 A 12/1996 Belleau et al.  
5,618,820 A 4/1997 Dionne  
5,618,964 A 4/1997 Cheng et al.  
5,627,186 A 5/1997 Cameron et al.  
5,663,159 A 9/1997 Starrett, Jr. et al.  
5,696,254 A 12/1997 Mansour et al.  
5,733,788 A 3/1998 Bischofberger  
5,744,596 A 4/1998 Mansour et al.  
5,756,706 A 5/1998 Mansour et al.  
5,763,606 A 6/1998 Mansour et al.  
5,792,756 A 8/1998 Starrett, Jr. et al.  
5,798,340 A 8/1998 Bischofberger et al.  
5,814,639 A 9/1998 Liotta et al.

(Continued)

#### FOREIGN PATENT DOCUMENTS

EP 0 182 024 A2 5/1986  
EP 0 206 459 A2 12/1986

(Continued)

#### OTHER PUBLICATIONS

Gilead Sciences Conference Call to Discuss Triangle Pharmaceuticals Acquisition dated Dec. 4, 2002, Ristig et al. (Tenofovir Disoproxil Fumarate, TDF) Therapy for Chronic Hepatitis B in Human Immunodeficiency Virus/Hepatitis B Virus—Coinfected Individuals for Whom Interferon-alpha and Lamivudine Therapy Have Failed, JID 2002; 186 pp. 1844-1847.\*  
Complaint for Patent Infringement against Teva Pharmaceuticals USA, Inc and Teva Pharmaceuticals Industries, Ltd. filed by Gilead Sciences, Inc. Case No. 08-CV-10838 (Dec. 12, 2008).  
Answer and Counterclaim against Gilead Sciences, Inc. filed by Teva Pharmaceuticals USA, Inc and Teva Pharmaceuticals Industries, Ltd. Case No. 08-CV-10838 (Feb. 5, 2009).  
Plaintiff's Reply to Teva's Counterclaim, filed by Gilead Sciences, Inc., Emory University Case No. 08-CV-10838 (Feb. 25, 2009).  
First Amended Complaint for Patent Infringement against Teva Pharmaceuticals USA, Inc and Teva Pharmaceuticals Industries, Ltd. filed by Gilead Sciences, Inc., Emory University Case No. 08-CV-10838 (Jul. 1, 2009).

(Continued)

*Primary Examiner* — Alton Pryor

(57) **ABSTRACT**

The present invention relates to therapeutic combinations of [2-(6-amino-purin-9-yl)-1-methyl-ethoxymethyl]-phosphonic acid diisopropoxycarbonyloxymethyl ester (tenofovir disoproxil fumarate, Viread®) and (2R, 5S, cis)-4-amino-5-fluoro-1-(2-hydroxymethyl-1,3-oxathiolan-5-yl)-(1H)-pyrimidin-2-one(emtricitabine, Emtriva™, (-)-cis FTC) and their physiologically functional derivatives. The combinations may be useful in the treatment of HIV infections, including infections with HIV mutants bearing resistance to nucleoside and/or non-nucleoside inhibitors. The present invention is also concerned with pharmaceutical compositions and formulations of said combinations of tenofovir disoproxil fumarate and emtricitabine, and their physiologically functional derivatives, as well as therapeutic methods of use of those compositions and formulations.

**26 Claims, No Drawings**